Ultragenyx resubmits gene therapy for rare neuro disease to FDA

Ultragenyx has resubmitted its approval request for a rare disease gene therapy after the FDA rejected it last summer. UX111 is an AAV gene therapy designed to treat Sanfilippo syndrome type A. The company is ...